MgShell announces the closing of a €1.14M investment round to accelerate the development of its innovative technologies for the treatment of eye diseases
Milan, April 22, 2025
MgShell, an Italian company in the MedTech spin-off sector of the Politecnico di Milano specialized in the development of innovative technologies for the treatment of eye diseases, announces the closing of a €1,140,000 investment round. The deal was led by Capital Cell and industry expert Dr. Andrea Giani, with the important participation of current investing partners, including members of the Investors Club through Simon Fiduciaria, Italian Angels for Biotech and Bios Line Holding.
Toward preclinical validation and market access
The funds will enable MgShell to accelerate the development and preclinical validation of its revolutionary technology, support product development, advance business development activities and strengthen the team. MgShell will continue working to complete the development of the technology, with the goal of bringing it to market as quickly as possible and offering an innovative solution to physicians and patients.
The support of strategic investors
“This investment represents a crucial step for MgShell, confirming the strength of our vision and the value of our technology. With the support of experienced and strategic investors, we are ready to accelerate our path to clinical validation and market access,” said Marco Ferroni, CEO of MgShell.
A real opportunity for innovation in retinal therapies
“We are excited to support MgShell on its growth path. Their technology represents an innovative solution in an area with a huge need for effective new therapies “, commented Daniel Oliver, Director of Capital Cell.
“I am convinced that MgShell can revolutionize retinal therapies with an approach that can reduce the treatment burden for patients, caregivers, and physicians,” added Andrea Giani, retinal specialist and investor.
Confidence in the team and technological potential
This second round represents a strong vote of confidence and will play a crucial role in achieving preclinical validation on schedule,” said Enrico Gianotti, Investor Club Champion.
“MgShell has the potential to revolutionize the ophthalmic industry by improving patients’ quality of life,” said Federica Girolami, Champion of Italian Angels for Biotech.
“We believe in the scientific and clinical value of this technology and the team’s expertise in addressing a clear and urgent need,” added Lucio Rovati, CEO of Rottapharm Biotech.
“After my experience with Next Sight, I recognized in MgShell the same potential for high-impact innovation in the ophthalmic field,” commented Paolo Tramonti, CEO of Bios Line Holding.
“From an investment and governance perspective, MgShell stands out for its sound management and ability to achieve key objectives. We have full confidence in the direction taken and the long-term value of the project,” concluded Stefano Gallucci, Advisor to Bios Line Holding.
